Shares of Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) were down 2.1% during mid-day trading on Friday . The company traded as low as C$1.85 and last traded at C$1.89. Approximately 80,575 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 135,165 shares. The stock had previously closed at C$1.93.
Cardiol Therapeutics Stock Down 2.1 %
The company has a market cap of C$132.07 million, a PE ratio of -4.30 and a beta of 0.70. The stock has a 50-day moving average of C$2.44 and a 200-day moving average of C$2.75. The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
- Five stocks we like better than Cardiol Therapeutics
- How to Calculate Inflation Rate
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What Are Some of the Best Large-Cap Stocks to Buy?
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
